Emyria logo

Emyria(ASX) EMD

Market CapA$33.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-71%
5 Year-80%
1 Year-39%
1 Month-13%
A$0.04
+2.44%
+0.00Today
Emyria last closing stock price
MetricPriceDate
Last closeAUD 0.042026-10-09
Emyria stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.67%AUD 0.052026-10-02
1 month-12.5%AUD 0.052026-09-09
3 month+10.53%AUD 0.042026-07-10
Year to date-28.81%AUD 0.062025-12-31
1 year-39.13%AUD 0.072025-10-09
3 year-39.13%AUD 0.072023-10-10
5 year-80%AUD 0.212021-10-08
Since inception-70.82%AUD 0.142020-02-12

Emyria Financials at a Glance

Market Cap

A$33.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.27M

Net Income (TTM)

-A$9.26M

EPS (TTM)

-A$0.01

P/E Ratio

-5.19

Dividend

A$0.00

Beta (Volatility)

-0.26 (Low)

Price

A$0.04

Volume

1,316,919

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.04 - A$0.08

Estimated Earnings Date

Mar 4, 2027

EMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emyria

Emyria Limited is a biotechnology firm focused on developing innovative therapies for medical conditions with limited treatment options. The company specializes in cannabinoid-derived pharmaceuticals and is exploring new MDMA-based drugs to address various health issues.

Products and Services
  • Development of cannabinoid-derived pharmaceuticals
  • Research on MDMA-based therapies for mental health
  • Pipeline includes EMD-RX5 and EMD-RX7 for various conditions
Growth Outlook
  • Recent quarterly revenue reached AUD 2.44 million, indicating strong market interest
  • Cash reserves of AUD 7.29 million support ongoing research and development
  • Strategic focus on unmet medical needs positions the company for future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 8.5 million reflects increasing demand
  • Current ratio of 4.36 suggests strong liquidity and financial health
  • Net income for the latest quarter was AUD -3.74 million, highlighting ongoing investment in R&D
Emyria Limited is positioned in the healthcare sector, specifically within biotechnology, and aims to address significant gaps in treatment options. The company's focus on cannabinoid and MDMA-based therapies aligns with growing interest in alternative medicine. Recent financial data indicates a solid revenue stream and healthy liquidity, which are crucial for sustaining research initiatives. The ongoing development of its product pipeline, particularly EMD-RX5 and EMD-RX7, showcases the company's commitment to innovation in healthcare.
AI Generated • Sep 29, 2026

Industry

Pharmaceuticals

CEO

Michael Winlo, MD, MBA

Website

emyria.com

Headquarters

Subiaco, WA 6008, AU

EMD Financials

Key Financial Metrics (TTM)

Gross Margin

-94.31%

Operating Margin

-161.58%

Net Income Margin

-157.60%

Return on Equity

-58.38%

Return on Capital

-65.08%

Return on Assets

-53.20%

Earnings Yield

-19.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$33.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

806.69M

Volume

1.32M

Avg. Volume

1.51M

Financials (TTM)

Gross Profit

-A$3.63M

Operating Income

-A$8.91M

EBITDA

-A$7.84M

Operating Cash Flow

-A$7.26M

Capital Expenditure

-A$380.05K

Free Cash Flow

-A$7.64M

Cash & ST Invst.

A$7.29M

Total Debt

A$787.38K

Emyria Performance Analysis

Emyria annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,592,466-12.6%
20242024-06-30AUD 2,202,71738.3%
20252025-06-30AUD 1,309,227-40.6%
20262026-06-30AUD 3,879,638196.3%
Emyria sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-40.9%
Q42025-06-3011.9%
Q22025-12-3195.4%
Q42026-06-3069.6%
Emyria annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.02-35.2%
20242024-06-30AUD -0.0380.2%
20252025-06-30AUD -0.01-78.1%
20262026-06-30AUD -0.0118.6%
Emyria sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-35.3%
Q42025-06-30-100.0%
Q22025-12-3123.9%
Q42026-06-30-31.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$2.44M

+119.3%

Gross Profit

-A$2.33M

-2155.3%

Gross Margin

-95.53%

N/A

Market Cap

A$33.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$5.65M

N/A

Employees

6

N/A

Net Income

-A$3.74M

-464.9%

EBITDA

-A$3.53M

-1436.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$7.29M

+365.5%

Total Debt

A$787.38K

-54.2%

Accounts Receivable

A$794.38K

+2490.6%

Inventory

A$329.34K

N/A

Long Term Debt

A$660.61K

-3.9%

Short Term Debt

A$126.77K

-87.7%

Return on Assets

-53.20%

N/A

Return on Invested Capital

-65.74%

N/A

Free Cash Flow

-A$2.83M

-4788.6%

Operating Cash Flow

-A$2.52M

-1252.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BDX.AXBCAL Diagnostics Limited
A$0.09+0.00%
MAP.AXMicroba Life Sciences Limited
A$0.05+2.00%
EYE.AXNova Eye Medical Limited
A$0.14+0.00%
NXS.AXNext Science Limited
A$0.15+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About EMD

What is the current price of Emyria?

Emyria is trading at A$0.04 per share.

What is the 52-week range for Emyria?

Over the past 52 weeks, Emyria has traded between A$0.04 and A$0.08.

How much debt does Emyria have?

As of the most recent reporting period, Emyria reported total debt of A$787.38K.

How much cash does Emyria have on hand?

Emyria reported A$7.29M in cash and cash equivalents in its most recent financial results.

What is Emyria’s dividend yield?

Emyria does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.